Cronos Group Inc (NASDAQ:CRON) has been assigned an average rating of “Hold” from the ten research firms that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $11.64.
Several equities analysts have issued reports on CRON shares. GMP Securities reaffirmed a “buy” rating on shares of Cronos Group in a report on Monday, November 19th. Jefferies Financial Group started coverage on shares of Cronos Group in a report on Monday, February 25th. They issued an “underperform” rating on the stock. Zacks Investment Research lowered shares of Cronos Group from a “hold” rating to a “sell” rating in a report on Wednesday, December 12th. CIBC started coverage on shares of Cronos Group in a report on Friday, January 18th. They issued a “sector outperform” rating on the stock. Finally, BMO Capital Markets lowered shares of Cronos Group from a “market perform” rating to an “underperform” rating and set a $21.43 price target on the stock. in a report on Monday. They noted that the move was a valuation call.
Shares of NASDAQ:CRON traded down $0.32 during trading on Friday, reaching $20.82. 7,198,626 shares of the company were exchanged, compared to its average volume of 17,941,396. The firm has a market cap of $3.78 billion and a PE ratio of 2,082.00. Cronos Group has a 12-month low of $5.12 and a 12-month high of $25.10.
Cronos Group Company Profile
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada.
Featured Story: Rule of 72
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.